Effect of Virtual Reality and Progressive Muscle Relaxation on Anxiety and Attention Among Cardiac Care Unit Patients

September 23, 2025 updated by: Alexandria University

Effect of Virtual Reality and Modified Progressive Muscle Relaxation Distraction Techniques on Anxiety and Attention Among Cardiac Care Unit Patients; RCT.

A randomized controlled trial with two parallel groups was conducted, to determine the effect of virtual reality (VR) and modified progressive muscle relaxation (MPMR) distraction techniques on anxiety, attention and getting distracted from the external environment among cardiac care unit patients.

The study is based on the following hypotheses:

H1: Patients who receive VR intervention have lower Hamilton Anxiety Rating (HAM-A) scores than those who receive MPMR intervention.

H2: Patients who receive VR intervention exhibit improvement in their physiological parameters than those who receive MPMR intervention.

H3: Patients who receive VR intervention have higher Attention/Distraction scores than those who receive MPMR intervention.

Study Overview

Status

Completed

Conditions

Detailed Description

This randomized controlled trial with two parallel groups was conducted in the cardiac care unit of Smouha Hospital, affiliated with Alexandria University, Egypt.

A total of 158 patients were recruited using a simple random sampling method and assigned to one of two groups to determine the effects of virtual reality (VR) and modified progressive muscle relaxation (MPMR) distraction techniques on anxiety, attention, and distraction from the external environment among cardiac care unit patients.

Four assessment tools were used:

  1. Sociodemographic and Clinical Assessment.
  2. Physiological Parameter Assessment.
  3. Hamilton Anxiety Rating Scale (HAM-A).
  4. Attention/Distraction Scale.

Study Type

Interventional

Enrollment (Actual)

158

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Alexandria, Egypt
        • Cardiac care unit of Smouha Hospital, which is affiliated to Alexandria University, Egypt.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Admitted to CCU for at least 3 days after stability.
  • Patients who are conscious and stable condition and all of whom exhibited varying levels of anxiety.

Exclusion Criteria:

- Patients with a history of neurological impairments such as motor, visual, and auditory disabilities and psychological disorders.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Virtual Reality Group (VR)

The intervention was administered three times per day, 10 minutes each session, for three consecutive days.

The VR goggles and headset phone were placed on the patient's head, straps secured, and lens spacing adjusted for a clear visual field. Patients were instructed to use head movements to control the cursor and interact with the virtual content. The 3D video clips with natural sceneries and background music were played to create a relaxing experience.

The VR goggles and headset phone were placed on the patient's head, straps secured, and lens spacing adjusted for a clear visual field. Patients were instructed to use head movements to control the cursor and interact with the virtual content. The 3D video clips with natural sceneries and background music were played to create a relaxing experience.
Other Names:
  • VR
Active Comparator: Modified Progressive Muscle Relaxation Group (MPMR)

The intervention was administered three times per day, 10 minutes each session, for three consecutive days.

The exercises applied to specific body parts while patients closed their eyes and practiced deep breathing, accompanied by background music.

The exercises applied to specific body parts while patients closed their eyes and practiced deep breathing, accompanied by background music.
Other Names:
  • MPMR

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of changes in physiological parameters between baseline and post-intervention scores for both groups.
Time Frame: Baseline physiological parameter assessments were conducted individually for each patient on the first day of the intervention. Post-intervention assessments were conducted during the same three shifts across the three-day period.
Compares the degree of change between baseline physiological parameters (heart rate and rhythm, respiratory rate and rhythm, oxygen saturation, blood pressure, and pain level) and post-intervention scores for both groups.
Baseline physiological parameter assessments were conducted individually for each patient on the first day of the intervention. Post-intervention assessments were conducted during the same three shifts across the three-day period.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of changes in anxiety levels between baseline and post-intervention scores for both groups.
Time Frame: Baseline anxiety level assessments were conducted individually for each patient on the first day of the intervention. Post-intervention assessments were conducted during the same three shifts across the three-day period.
Compares the degree of change between baseline anxiety level (Hamilton Anxiety Rating Scale, HAM-A) and post-intervention scores for both groups.
Baseline anxiety level assessments were conducted individually for each patient on the first day of the intervention. Post-intervention assessments were conducted during the same three shifts across the three-day period.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of attention / distraction levels between both groups at the end of the intervention.
Time Frame: Attention / distraction levels were assessed individually for each patient during the night shift on the third day after completing all nine intervention sessions.
Compares attention / distraction levels using the Attention / Distraction Scale for both groups.
Attention / distraction levels were assessed individually for each patient during the night shift on the third day after completing all nine intervention sessions.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Sajeda A Shdaifat, PhD-Cand, Alexandria University
  • Study Director: Azza H El-Soussi, Professor, Alexandria University
  • Study Director: Mohamed I Sanhoury, Asst. Prof, Alexandria University
  • Study Director: Eman A Ali, Asst. Prof, Alexandria University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 20, 2025

Primary Completion (Actual)

May 20, 2025

Study Completion (Actual)

May 24, 2025

Study Registration Dates

First Submitted

September 21, 2023

First Submitted That Met QC Criteria

January 18, 2024

First Posted (Actual)

January 22, 2024

Study Record Updates

Last Update Posted (Estimated)

September 26, 2025

Last Update Submitted That Met QC Criteria

September 23, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Distraction Techniques

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety

Clinical Trials on Virtual reality

Subscribe